Infliximab (IFX), an anti-tumor necrosis factor alpha (TNFα) therapy, has significantly advanced IBD treatment.6,7 However, approximately 30% of patients do not respond initially, and approximately 50% lose response during maintenance,8 often due to suboptimal IFX trough concentrations and antidrug antibodies.9 This evidence concerns the gene TNF and inflammatory bowel disease.